Screen Reader Mode Icon
Please complete the following pre-activity survey and evaluation questions so we can review our goals, objectives, and topics for future events. If you complete the Evaluation Questions and provide contact information, you will receive a Certificate of Participation.

Question Title

* 1. Name

Question Title

* 2. Title (MD/DO, NP/PA, PharmD, Other):

Question Title

* 3. Speciality (ex. Urologist, medical oncologist, pathologist, genetic counselor, etc):

Question Title

* 4. Organization

Question Title

* 5. City & Country

Question Title

* 6. Email address

Question Title

* 7. What drug class do poly(ADP)-ribose polymerase (PARP) inhibitors belong to?

Question Title

* 8. What is the mechanism of action of poly(ADP)-ribose polymerase (PARP) inhibitors?

Question Title

* 9. Which one of the following drugs is approved for metastatic castrate-resistant prostate cancer?

Question Title

* 10. Which one of the following trials supports the use of rucaparib in metastatic prostate cancer?

Question Title

* 11. Which of the following combination regimens has not been tried in prostate cancer?

Question Title

* 12. Prostate Cancer Symposium: Please rate your current level of knowledge in Learning Objective #1: “Explaining mechanisms of action and risks associated with PARPi alone, as well as in combination with AR inhibitors currently used in practice”:

Question Title

* 13. Prostate Cancer Symposium: Please rate your current level of knowledge in Learning Objective #2: “Identifying and listing gene mutations that are predictive biomarkers to identify PARPi +AR inhibitor-responding mCRPC patients”:

Question Title

* 14. Which one of the following anti-PD-(L)1 drugs has not been approved by the FDA for urothelial carcinoma?

Question Title

* 15. Maintenance therapy for la/mUC patients has now been recommended as a standard of care by both the National Comprehensive Cancer Network and the European Society for Medical Oncology?

Question Title

* 16. The JAVELIN clinical trial demonstrated which one of the following:

Question Title

* 17. A 65-year-old female patient with locally advanced UC who has received 4 cycles of 1L platinum-containing chemotherapy shows an increased overall survival benefit following chemotherapy. Following a standard Response Evaluation Criteria in Solid Tumours, the patient’s tumour diameter has only increased by 5%. Current data from prospective clinical trials and real-world studies suggest that this patient:

Question Title

* 18. A 75-year-old male who is cisplatin-ineligible received gem-carbo for metastatic disease and had disease progression- received pembrolizumab and progressed within 3 months. He has significant neuropathy. The tumour has an FGFR3 mutation.
What will you use next?

Question Title

* 19. Urothelial Carcinoma Symposium: Please rate your current level of knowledge in Learning Objective #1: “Understand and explain relevant and current clinical trials and updates regarding immunotherapy as maintenance therapy in la/mUC patients”:

Question Title

* 20. Urothelial Carcinoma Symposium: Please rate your current level of knowledge in Learning Objective #2: “Understand which la/mUC patients should be followed up with immunotherapy maintenance treatment”:

Question Title

* 21. A 59-year-old man is diagnosed with chronic-phase chronic myeloid leukemia and started on imatinib as first-line treatment. He meets his 3-month milestone of PCR measuring BCR-ABL1 <10% IS, and this is measured at 0.23% IS by 9 months. However, at 1 year his PCR is back up to 7% IS. A kinase domain mutation analysis is checked and reveals the presence of a T315I mutation. Which TKI would be the most appropriate second-line treatment option for this patient?

Question Title

* 22. In the ASCEMBL trial, asciminib was compared to bosutinib as third-line treatment. What is the only adverse event which was more prevalent in the Asciminib arm compared to bosutinib treated patients?

Question Title

* 23. Where does asciminib bind to the BCR-ABL1 protein?

Question Title

* 24. A 54-year-old man was diagnosed with CML 12 months ago. The patient was started on imatinib 400 mg daily. The patient has mild fatigue and diarrhea from imatinib. PCR at 3 months demonstrated a BCR-ABL1 level 7.1% IS. At 12 months, the BCR-ABL1 increased to 12%. What is your next step?

Question Title

* 25. A 60-year-old woman was diagnosed with CML 12 months ago. The patient was started on imatinib 400 mg daily. Has mild fatigue and diarrhea from imatinib. PCR at 3 months demonstrated a BCR-ABL1 level 7.1% IS. At 12 months, the BCR-ABL1 increased to 12%. The patient is adherent to her medications. A BCR-ABL1 mutation analysis demonstrated the presence of a T315I mutation. What is your next step?

Question Title

* 26. CML Therapy Symposium: Please rate your current level of knowledge in Learning Objectives:

0 of 26 answered
 

T